Pharmaceuticals

Case Solution for Medfield Pharmaceuticals

Complete Case details are given below :

Case Name : Medfield Pharmaceuticals

Authors : Marc Lipson, Jenny Mead, Jared Harris

Source : Darden School of Business

Case ID : UV5632

Discipline : Finance

Case Length : 13 pages

Solution Sample availability : YES

Plagiarism : NO (100% Original work)

Description for case is given below :

Susan Johnson, founder and CEO of Medfield Pharmaceuticals, is faced with conflicting recommendations for extending the patent life of the company’s flagship product, Fleximat, scheduled to go off patent in two years. With only three other products in Medfield’s lineup of medications, one of which has only just received U.S. Food and Drug Administration approval, strategic management of the company’s product pipeline is of paramount importance. But a recent $750 million offer to purchase the company has entirely shifted her focus. With this offer, Johnson has the opportunity to exit the business on a high note. Before making her recommendation, Johnson has to determine the value of the company, with a careful review of its existing and potential future products. But this is more than simply a financial decision, since Johnson-and Medfield employees in general-believe that the company is engaged in critically important work. This case is meant for undergraduate, MBA, executive education, and MBA exec audiences. It is taught as a core course, “Financial Management and Policies,” at the Darden Graduate School of Business Administration.

Click Here to place your order

Place your order at casesolutionshub (AT)gmail(dot)com if you want to solve above case.

Cordially,

Case Solutions Hub

Case Solution for Farming Pharmaceuticals: Ventria Bioscience and the Controversy over Plant-Made Medicines

Complete Case details are given below :

Case Name : Farming Pharmaceuticals: Ventria Bioscience and the Controversy over Plant-Made Medicines

Authors : Anne T. Lawrence

Source : Ivey Publishing

Case ID : 909M11

Discipline : Entrepreneurship

Case Length : 11 pages

Solution Sample availability : YES

Plagiarism : NO (100% Original work)

Description for case is given below :

How can a biotechnology start-up navigate a complex regulatory and stakeholder terrain to bring to market an innovative product with potentially significant public health benefits? This case focuses on the challenges facing Ventria Bioscience, a small biotechnology firm based in California. The company had developed an innovative technology for “growing” medical proteins useful in the treatment of childhood diarrhea in genetically modified rice. The company’s efforts to obtain regulatory approval in California to commercialize its invention met with a firestorm of opposition from a wide range of stakeholders, including environmentalists, food safety activists, consumer advocates and rice farmers. The case presents the hurdles faced by Ventria as it has attempted to commercialize its invention in the context of the broader debate over the ethics of plant-based medicines. This case is suitable for an upper-division undergraduate or graduate course in entrepreneurship, small business, the management of technology or biotechnology. In such a course, it is best positioned in a discussion of the regulatory environment and stakeholder relations. Alternatively, the case may be used in a segment on technology or stakeholder relationships in a course in business and society.

Click Here to place your order

Place your order at casesolutionshub (AT)gmail(dot)com if you want to solve above case.

Cordially,

Case Solutions Hub

Case Solution for Orchid Chemicals & Pharmaceuticals Limited: Managing the Value Chain Transformation

Complete Case details are given below :

Case Name : Orchid Chemicals & Pharmaceuticals Limited: Managing the Value Chain Transformation

Authors : Ravi Ravichandran, Ankur Roy

Source : Ivey Publishing

Case ID : 906M71

Discipline : Organizational Behavior

Case Length : 26 pages

Solution Sample availability : YES

Plagiarism : NO (100% Original work)

Description for case is given below :

Orchid Chemicals & Pharmaceuticals Limited (Orchid) is an Indian pharmaceutical company which began operations in 1994. Over a span of 10 years, the turnover of this company has increased from US$11 million to US$153 million. The company’s profit after tax registered a five-fold increase, from US$1.3 million to US$6.8 million, in the corresponding period. Early success was a combination of pricing flexibility, lower production cost, and business opportunities in unregulated markets. Orchid decided to explore opportunities for the manufacture of generic drugs in the regulated markets and formulations in the domestic market. Diversification to basic research was also considered. Cooperation and joint ventures were the primary route to expand and explore new molecule discovery. By 2005, Orchid was no longer a single-product company, its business had widened to multiple products in bulk, formulations, and generics, in both regulated and unregulated markets. Orchid was making its presence felt in its novel drug delivery systems and new drug development processes. In 2005, Orchid faced several challenges related to financial leverage and risks, leadership, managerial challenges associated with joint ventures, balancing the new business model, setting global trends in being a pioneer in the industry, addressing shareholders’ concerns, and evolving an appropriate organization culture and process.

Click Here to place your order

Place your order at casesolutionshub (AT)gmail(dot)com if you want to solve above case.

Cordially,

Case Solutions Hub

Case Solution for CFR Pharmaceuticals: Potential Synergies in Africa

Complete Case details are given below :

Case Name : CFR Pharmaceuticals: Potential Synergies in Africa

Authors : Charlene Lew

Source : Ivey Publishing

Case ID : W14589

Discipline : Organizational Behavior

Case Length : 14 pages

Solution Sample availability : YES

Plagiarism : NO (100% Original work)

Description for case is given below :

The third-generation leader of CFR Pharmaceuticals had been successful in executing a strategy of consolidating pharmaceutical firms across Latin America. As part of the company’s expansion strategy, the CEO explored opportunities to develop multiple sources of growth and expand CFR Pharmaceutical’s footprint in emerging markets; to do this, he found a company in South Africa, Adcock Ingram, to acquire. The combined company would offer CFR product synergy and diversification, improved manufacturing and distribution capabilities and a unique emerging market footprint in 23 countries. In the process of making an offer of approximately US$1.2 billion to acquire the company, the CEO faced increased interest in Adcock from other potential acquirers. He also encountered a series of difficulties when an Adcock shareholder resisted the acquisition, but CFR maintained the consistent support of the Adcock Ingram board.

Click Here to place your order

Place your order at casesolutionshub (AT)gmail(dot)com if you want to solve above case.

Cordially,

Case Solutions Hub

Case Solution for Syntonix Pharmaceuticals

Complete Case details are given below :

Case Name : Syntonix Pharmaceuticals

Authors : Raymond M. Kinnunen, Susan F. Sieloff, Robert Young

Source : North American Case Research Association (NACRA)

Case ID : NA0034

Discipline : Finance

Case Length : 15 pages

Solution sample availability : YES

Plagiarism : NO (100% Original work)

Description for case is given below :

Syntonix Pharmaceuticals, a Boston biopharmaceutical startup company, was seeking additional financing for growth. The company had developed and patented an improved delivery platform for long-acting biopharmaceuticals and then utilized that technology to develop new therapies to treat chronic diseases. The Transceptor® technology utilized a unique biological pathway to allow efficient delivery of SynFusion™ drug therapies. Several companies licensed the technologies in joint development deals to address several different conditions: Hemophilia B, autoimmune disorders, and infertility, as well as for use in enhanced peptide inhalation. The company had used up Angel money and Rounds A and B of venture capital financing and was looking for an additional $80 – $100 million for growth. In September 2006, Syntonix was in negotiations with a VC syndicate to gain a ‘C’ Round of funding. One member of the proposed syndicate, Biogen Idec, indicated interest in buying Syntonix outright. The founders needed to make a decision about the offer.

Click Here to place your order

Place your order at casesolutionshub (AT)gmail(dot)com if you want to solve above case.

Cordially,

Case Solutions Hub